Search alternatives:
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
a largest » _ largest (Expand Search), a large (Expand Search)
a latest » _ latest (Expand Search), _ latent (Expand Search), a late (Expand Search)
a latent » _ latent (Expand Search), _ patent (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), i large (Expand Search)
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
a largest » _ largest (Expand Search), a large (Expand Search)
a latest » _ latest (Expand Search), _ latent (Expand Search), a late (Expand Search)
a latent » _ latent (Expand Search), _ patent (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), i large (Expand Search)
-
101
Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
102
Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
Class I SLA expression is increased in the TSST-1 stimulated CD4+ cells.
Published 2020“…The left two panels show the representative pattern of FSC/SSC after 72 hrs of culture with/without TSST-1 stimulation. As the large cells are increased by TSST-1 stimulation, a small and large lymphocyte gate was used for the analysis. …”
-
119
-
120
Table_1_Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma.XLSX
Published 2021“…<p>The clinical and molecular characteristics of localized diffuse large B-cell lymphoma (DLBCL) with single nodal (SN) or single extranodal (SE) involvement remain largely elusive in the rituximab era. …”